Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 UCB Submits MAA for Vimpat | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

UCB Submits MAA for Vimpat

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schwarz Pharma, a subsidiary of UCB, submitted a MAA to the EMEA for Vimpat to treat diabetic neuropathic pain and it has been accepted for review.

Vimpat is an anticonvulsant drug with a novel dual mode of action acting on CRMP-2 (collapsing response mediator protein 2) and sodium channel slow inactivation. Diabetic neuropathic pain is a common chronic pain syndrome from which approximately eleven million people with diabetes suffer. Neuropathic pain is caused by damage to a peripheral or central nerve and can lead to spontaneous sensations of pain.

An application for marketing approval for Vimpat as an adjunctive therapy for adult patients with epilepsy with partial onset seizures was accepted for review by the EMEA in May 2007. The company plans to file for approval in the U.S. in 4Q2007.

Also, clinical studies with lacosamide in additional indications such as fibromyalgia, osteoarthritis and migraine prophylaxis, have been initiated, with first results expected in 2008.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters